Main Article Content
Although systemic thrombolysis and endovascular treatment have revolutionized modern stroke treatment, the majority of patients do not qualify for either treatment paradigm. Hence, novel adjuvant therapeutic strategies are required. This chapter provides an overview of our current understanding of novel therapeutic strategies in preclinical stroke models. The chapter is organized in three major parts to cover the acute, subacute, and chronic phases of ischemic stroke. The potential of various pharmacological agents, stem cells, microRNAs, and extracellular vesicles as therapeutic avenues along with the progress and challenges are discussed.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright of individual chapters belongs to the respective authors. The authors grant unrestricted publishing and distribution rights to the publisher. The electronic versions of the chapters are published under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). Users are allowed to share and adapt the chapters for any non-commercial purposes as long as the authors and the publisher are explicitly identified and properly acknowledged as the original source. The books in their entirety are subject to copyright by the publisher. The reproduction, modification, republication and display of the books in their entirety, in any form, by anyone, for commercial purposes are strictly prohibited without the written consent of the publisher.